alirocumab vs atorvastatin
PlainMeds reviewed this comparison against our methodology in August 2026. It places FDA and CMS record fields side by side, without recommending either medication.
Side-by-side comparison of alirocumab and atorvastatin. Data from FDA drug databases (Orange Book, NDC Directory, recalls, shortages) covering 20,000+ approved drugs, plus CMS pricing; see our methodology.
Praluent
Lipitor
Praluent is a medicine that can lower cholesterol. It can also lower the risk of heart problems like heart attack or stroke in some adults.
Atorvastatin is a drug that lowers cholesterol and reduces the risk of heart problems and stroke. It belongs to a class of drugs called statins.
Praluent is used to lower LDL cholesterol (bad cholesterol). It is used along with diet and exercise in adults with high cholesterol. It is also used in adults and children 8 years and older who have a genetic condition that causes high cholesterol.
Atorvastatin is used to lower bad cholesterol (LDL) and triglycerides in your blood. It can help prevent heart attacks, strokes, and the need for heart procedures in adults with heart disease or risk factors for it. It is also used in children 10 years and older with certain inherited cholesterol problems.
Praluent is a PCSK9 inhibitor. It works by blocking a protein in your body called PCSK9. Blocking this protein helps your body remove LDL cholesterol from your blood.
Atorvastatin works by blocking a substance your body needs to make cholesterol. This helps to lower the amount of cholesterol in your blood. Lowering cholesterol can help prevent heart disease.
- • Injection site reactions (redness, itching, swelling, pain)
- • Flu
- • Muscle pain
- • Diarrhea
- • Common cold symptoms
- • Joint pain
- • Diarrhea
- • Pain in arms or legs
- • Urinary tract infection
- Myalgia 1,655
- Product Dose Omission 1,364
- Injection Site Pain 1,278
- Muscle Spasms 1,162
- Arthralgia 1,053
- Fatigue 13,812
- Nausea 12,425
- Type 2 Diabetes Mellitus 11,244
- Diarrhoea 11,037
- Dyspnoea 11,029
Serious allergic reactions have happened with Praluent, sometimes requiring hospitalization. If you have signs of a serious allergic reaction, stop using Praluent and get medical help right away.
Atorvastatin can cause muscle problems, including muscle pain, tenderness, or weakness. In rare cases, this can lead to serious kidney damage. Tell your doctor right away if you have unexplained muscle pain, tenderness, or weakness, especially if you also have a fever or feel sick. Atorvastatin can also cause liver problems. Your doctor may do blood tests to check your liver before you start taking atorvastatin and while you are taking it.
There is not enough information about Praluent use during pregnancy to know if it is safe. If you are pregnant or plan to become pregnant, talk to your doctor before using Praluent.
Atorvastatin can harm an unborn baby. You should not take atorvastatin if you are pregnant or planning to become pregnant. It is also not recommended to breastfeed while taking atorvastatin.
Also Compare, Nearby Drugs
Compare alirocumab with
Compare atorvastatin with
How to Read This alirocumab vs atorvastatin Comparison
alirocumab is classified in the PCSK9 Inhibitor drug class, while atorvastatin sits within the HMG-CoA Reductase Inhibitor (Statin) class. Drugs from different classes work through distinct mechanisms, so a head-to-head comparison illustrates trade-offs rather than equivalence. Both drugs are prescription-only, so a licensed provider must authorize use.
Adverse event totals above are pulled from the FDA's Adverse Event Reporting System (FAERS). For these top-ranked reactions alone, alirocumab has 6,512 submissions while atorvastatin has 59,547. Those figures reflect cumulative reporting volume, not per-patient risk, so older, widely dispensed drugs typically look worse on count alone. No direct interaction between these two drugs is listed in our FDA-derived dataset, though co-prescription still warrants pharmacist review. Serious warnings, pregnancy guidance, and contraindications can differ even when indications overlap.
A table cannot represent individual circumstances. Data here is sourced from FDA Structured Product Labels (SPL) and FAERS, both of which update as manufacturers and clinicians submit new information. This registry does not provide medical, treatment, substitution, or medication-change directions for alirocumab or atorvastatin.
Registry boundary: This comparison displays source-record fields and does not provide individualized medical direction.